Research ArticleArticle
Continued Benefit of Tocilizumab Plus Disease-modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8 of Treatment
Edward C. Keystone, Andrew Anisfeld, Sarika Ogale, Jenny N. Devenport and Jeffrey R. Curtis
The Journal of Rheumatology January 2014, jrheum.130489; DOI: https://doi.org/10.3899/jrheum.130489
Edward C. Keystone
From Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, Ontario, Canada; US Medical Affairs-Immunology and Biometrics and Health Outcomes, Genentech, South San Francisco, California; University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Curtis receives support from the US National Institutes of Health (AR 053351) and has received research grants from the Agency for Healthcare Research and Quality, and consultancy fees from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Centocor Inc., CORRONA, Crescendo Therapeutics LLC, F. Hoffmann-La Roche Inc., Genentech, Pfizer Pharmaceuticals, and UCB. Dr. Keystone has received research grants from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genzyme, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB; consultancy fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; lecture/speakers honoraria from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Janssen Inc., Merck Sharp & Dohme, Pfizer Pharmaceuticals, and UCB; board membership fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; and fees for participation in data monitoring boards from F. Hoffmann-La Roche Inc. Drs. Anisfeld, Ogale, and Devenport are employees of Genentech, a member of the Roche group. E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; A. Anisfeld, PhD, US Medical Affairs–Immunology; S. Ogale, PhD; J.N. Devenport, PhD, Biometrics and Health Outcomes, Genentech; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology. Address correspondence to Dr. E.C. Keystone, Professor of Medicine, University of Toronto Faculty of Medicine, 1 King’s College Circle, Medical Sciences Building, Room 2109, Toronto, Ontario M5S 1A8, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 8, 2013.
Andrew Anisfeld
From Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, Ontario, Canada; US Medical Affairs-Immunology and Biometrics and Health Outcomes, Genentech, South San Francisco, California; University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Curtis receives support from the US National Institutes of Health (AR 053351) and has received research grants from the Agency for Healthcare Research and Quality, and consultancy fees from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Centocor Inc., CORRONA, Crescendo Therapeutics LLC, F. Hoffmann-La Roche Inc., Genentech, Pfizer Pharmaceuticals, and UCB. Dr. Keystone has received research grants from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genzyme, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB; consultancy fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; lecture/speakers honoraria from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Janssen Inc., Merck Sharp & Dohme, Pfizer Pharmaceuticals, and UCB; board membership fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; and fees for participation in data monitoring boards from F. Hoffmann-La Roche Inc. Drs. Anisfeld, Ogale, and Devenport are employees of Genentech, a member of the Roche group. E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; A. Anisfeld, PhD, US Medical Affairs–Immunology; S. Ogale, PhD; J.N. Devenport, PhD, Biometrics and Health Outcomes, Genentech; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology. Address correspondence to Dr. E.C. Keystone, Professor of Medicine, University of Toronto Faculty of Medicine, 1 King’s College Circle, Medical Sciences Building, Room 2109, Toronto, Ontario M5S 1A8, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 8, 2013.
Sarika Ogale
From Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, Ontario, Canada; US Medical Affairs-Immunology and Biometrics and Health Outcomes, Genentech, South San Francisco, California; University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Curtis receives support from the US National Institutes of Health (AR 053351) and has received research grants from the Agency for Healthcare Research and Quality, and consultancy fees from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Centocor Inc., CORRONA, Crescendo Therapeutics LLC, F. Hoffmann-La Roche Inc., Genentech, Pfizer Pharmaceuticals, and UCB. Dr. Keystone has received research grants from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genzyme, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB; consultancy fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; lecture/speakers honoraria from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Janssen Inc., Merck Sharp & Dohme, Pfizer Pharmaceuticals, and UCB; board membership fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; and fees for participation in data monitoring boards from F. Hoffmann-La Roche Inc. Drs. Anisfeld, Ogale, and Devenport are employees of Genentech, a member of the Roche group. E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; A. Anisfeld, PhD, US Medical Affairs–Immunology; S. Ogale, PhD; J.N. Devenport, PhD, Biometrics and Health Outcomes, Genentech; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology. Address correspondence to Dr. E.C. Keystone, Professor of Medicine, University of Toronto Faculty of Medicine, 1 King’s College Circle, Medical Sciences Building, Room 2109, Toronto, Ontario M5S 1A8, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 8, 2013.
Jenny N. Devenport
From Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, Ontario, Canada; US Medical Affairs-Immunology and Biometrics and Health Outcomes, Genentech, South San Francisco, California; University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Curtis receives support from the US National Institutes of Health (AR 053351) and has received research grants from the Agency for Healthcare Research and Quality, and consultancy fees from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Centocor Inc., CORRONA, Crescendo Therapeutics LLC, F. Hoffmann-La Roche Inc., Genentech, Pfizer Pharmaceuticals, and UCB. Dr. Keystone has received research grants from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genzyme, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB; consultancy fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; lecture/speakers honoraria from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Janssen Inc., Merck Sharp & Dohme, Pfizer Pharmaceuticals, and UCB; board membership fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; and fees for participation in data monitoring boards from F. Hoffmann-La Roche Inc. Drs. Anisfeld, Ogale, and Devenport are employees of Genentech, a member of the Roche group. E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; A. Anisfeld, PhD, US Medical Affairs–Immunology; S. Ogale, PhD; J.N. Devenport, PhD, Biometrics and Health Outcomes, Genentech; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology. Address correspondence to Dr. E.C. Keystone, Professor of Medicine, University of Toronto Faculty of Medicine, 1 King’s College Circle, Medical Sciences Building, Room 2109, Toronto, Ontario M5S 1A8, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 8, 2013.
Jeffrey R. Curtis
From Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Toronto, Ontario, Canada; US Medical Affairs-Immunology and Biometrics and Health Outcomes, Genentech, South San Francisco, California; University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, USA. Funding for manuscript preparation was provided by F. Hoffmann-La Roche Ltd. Dr. Curtis receives support from the US National Institutes of Health (AR 053351) and has received research grants from the Agency for Healthcare Research and Quality, and consultancy fees from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Centocor Inc., CORRONA, Crescendo Therapeutics LLC, F. Hoffmann-La Roche Inc., Genentech, Pfizer Pharmaceuticals, and UCB. Dr. Keystone has received research grants from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genzyme, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB; consultancy fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; lecture/speakers honoraria from Abbott Laboratories, Amgen Inc., Bristol-Myers Squibb, Janssen Inc., Merck Sharp & Dohme, Pfizer Pharmaceuticals, and UCB; board membership fees from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Biotest, Bristol-Myers Squibb, Centocor Inc., Genentech Inc., Merck Sharp & Dohme, Nycomed, Pfizer Pharmaceuticals, and UCB; and fees for participation in data monitoring boards from F. Hoffmann-La Roche Inc. Drs. Anisfeld, Ogale, and Devenport are employees of Genentech, a member of the Roche group. E.C. Keystone, MD, FRCPC, Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; A. Anisfeld, PhD, US Medical Affairs–Immunology; S. Ogale, PhD; J.N. Devenport, PhD, Biometrics and Health Outcomes, Genentech; J.R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology. Address correspondence to Dr. E.C. Keystone, Professor of Medicine, University of Toronto Faculty of Medicine, 1 King’s College Circle, Medical Sciences Building, Room 2109, Toronto, Ontario M5S 1A8, Canada. E-mail: edkeystone@mtsinai.on.ca. Accepted for publication October 8, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Continued Benefit of Tocilizumab Plus Disease-modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8 of Treatment
Edward C. Keystone, Andrew Anisfeld, Sarika Ogale, Jenny N. Devenport, Jeffrey R. Curtis
The Journal of Rheumatology Jan 2014, jrheum.130489; DOI: 10.3899/jrheum.130489
Continued Benefit of Tocilizumab Plus Disease-modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8 of Treatment
Edward C. Keystone, Andrew Anisfeld, Sarika Ogale, Jenny N. Devenport, Jeffrey R. Curtis
The Journal of Rheumatology Jan 2014, jrheum.130489; DOI: 10.3899/jrheum.130489